Posted by Michael Wonder on 17 Oct 2016
Sofosbuvir with velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications
17 October 2016 - Historical comparisons and considerations of individual study arms unsuitable for conclusions on the other research questions.
The drug combination sofosbuvir with velpatasvir (Epclusa) has been approved since July 2016 for the treatment of patients with chronic hepatitis C. In an early benefit assessment, the German IQWiG has now examined whether the combination has an added benefit for the patients. In the assessment, a distinction was made regarding type of virus (genotype 1 to 6) and liver status (without cirrhosis, with compensated cirrhosis, and with decompensated cirrhosis).
According to the findings, an added benefit in comparison with the respective appropriate comparator therapy was not proven for eight of ten research questions because no suitable study data were available. There was a hint of considerable added benefit for one research question, and a hint of a non-quantifiable added benefit for another one.
